Global /South Korea /Healthcare /Biotechnology /261780

CHA Vaccine Research Institute

261780

• KRX: 261780 • Delayed

3,895KRW -2.3%

2.50 USD

As of 7 June 2026, CHA Vaccine Research Institute has a market cap of $68.27M USD, ranking #28297 globally and #1492 in South Korea. It ranks #2562 in the Healthcare sector, and #497 in the Biotechnology industry.

Global Rank

28297

Country Rank

1492

Sector Rank

2562

Industry Rank

497

Key Stats

Market Cap

$68.27MUSD

104.64B KRW

Enterprise Value

$57.57MUSD

89.81B KRW

Revenue (TTM)

$103.48KUSD

158.62M KRW

EBITDA (TTM)

-$8.86MUSD

-13.82B KRW

Net Income (TTM)

-$10.47MUSD

-16.04B KRW

PS Ratio

659.7

PB Ratio

8.8

Company Profile

Country (HQ)

South Korea

Sector

Healthcare

Industry

Biotechnology

CEO

Jungsun Yum open_in_new

Founded

2000

Website

chavaccine.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-2.3%	16%	-0.1%	37%	43%	41%	34%	-25%	-78%

News

Markets

Exchange	Ticker	Price	Quotes
Korea Exchange (KRX) MIC: XKRX PRIMARY	261780 CHA Vaccine Research Institute Co Ltd Ordinary Shares ISIN: KR7261780001 Shares Out.: Shares Outstanding: 26.913M¹ Shares Float: 21.31M² TV: TradingView: KRX: 261780 SA: Stock Analysis: KRX: 261780 YF: Yahoo Finance: 261780.KS GF: Google Finance: KRX: 261780 BA: Barron's: 261780 MS: Morningstar: XKRX: 261780	3,895 KRW	TV: TradingView: KRX: 261780 SA: Stock Analysis: KRX: 261780 YF: Yahoo Finance: 261780.KS GF: Google Finance: KRX: 261780 BA: Barron's: 261780 MS: Morningstar: XKRX: 261780

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About CHA Vaccine Research Institute

Cha Vaccine Research Institute Co., Ltd., a research-oriented biotechnology company, researches and develops a range of vaccine products for infectious and chronic diseases. Its product pipeline includes HBV vaccine that is in Phase IIb planning for the prevention of hepatitis B; Adjuvanted HBV vaccine that is in Phase I/IIa for the treatment of chronic hepatitis B; and VZV Vaccine, which is in pre-clinical planning stage for the prevention of Herpes Zoster. The company also develops influenza vaccine, recombinant MBL, TB vaccine, and cancer vaccine, as well as anti-cancer immunotherapy drugs. Cha Vaccine Research Institute Co., Ltd. was incorporated in 2000 and is headquartered in Seongnam-si, South Korea.

Similar Companies

Industry: Biotechnology (South Korea)

Name	Market Cap (USD) diff.	PE	Country
Samsung Biologics Co.,Ltd. KRX: 207940	$44.48B 68.19T KRW 65K%	35.5	South Korea
Celltrion, Inc. KRX: 068270	$27.89B 42.76T KRW 41K%	43.8	South Korea
ALTEOGEN Inc. KRX: 196170	$13.27B 20.33T KRW 19K%	146.6	South Korea
HLB Co., Ltd. KRX: 028300	$5.46B 8.37T KRW 8K%	-	South Korea
Peptron, Inc. KRX: 087010	$3.96B 6.07T KRW 6K%	-	South Korea
SK bioscience Co.,Ltd. KRX: 302440	$2.23B 3.42T KRW 3K%	-	South Korea

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 267K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 234K%	19.0	United States
argenx SE EBR: ARGX	$48.08B 41.39B EUR 70K%	39.9	Netherlands
CSL Ltd. ASX: CSL	$43.01B 60.27B AUD 63K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.72B 33.71B CHF 62K%	37.2	Switzerland
Natera, Inc. NASDAQ: NTRA	$27.6B 40K%	-	United States

chevron_leftBack